Supernus Pharmaceuticals Inc SUPN Financial and Strategic SWOT Analysis Review [Report Updated: 27032018] Prices from USD $125

11:37 EDT 11 Aug 2018 | BioPortfolio Reports

Supernus Pharmaceuticals Inc SUPN Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.

Corporate strategy Analyst's summarization of the company's business strategy.

SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history Progression of key events associated with the company.

Major products and services A list of major products, services and brands of the company.

Key competitors A list of key competitors to the company.

Key employees A list of the key executives of the company.

Executive biographies A brief summary of the executives' employment history.

Key operational heads A list of personnel heading key departments/functions.

Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


Supernus Pharmaceuticals Inc Supernus is a specialty pharmaceutical company which develops and commercializes products for the treatment of central nervous system CNS diseases. The company's neurology portfolio consists of Oxtellar XR oxcarbazepine, an adjunct therapy for the treatment of partial seizures; and Trokendi XR topiramate, an initial monotherapy against partial onset or primary generalized tonicclonic seizures and an adjunct therapy for the treatment of primary generalized tonicclonic seizures associated with LennoxGastaut syndrome. Its technology platforms include Microtrol multiparticulate delivery platform, Solutrol matrix delivery platform and EnSoTrol osmotic delivery system. The company operates through its subsidiary Supernus Europe Ltd. Supernus is headquartered in Rockville, Maryland, the US.

Supernus Pharmaceuticals Inc Key Recent Developments

Mar 14,2018: Supernus Pharmaceuticals May Add Up To 160 New Jobs in Montgomery County

Feb 27,2018: Supernus Announces Record Full Year 2017 Financial Results, Exceeding Operating Earnings Guidance

Nov 06,2017: Supernus Announces Third Quarter 2017 Financial Results

Aug 02,2017: Supernus Announces Record Second Quarter 2017 Financial Results

May 09,2017: Supernus Announces First Quarter 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: Supernus Pharmaceuticals Inc SUPN Financial and Strategic SWOT Analysis Review [Report Updated: 27032018] Prices from USD $125


More From BioPortfolio on "Supernus Pharmaceuticals Inc SUPN Financial and Strategic SWOT Analysis Review [Report Updated: 27032018] Prices from USD $125"

Quick Search


Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...